Timothy P. Noyes - 07 Mar 2023 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
07 Mar 2023
Net transactions value
$0
Form type
4
Filing time
08 Mar 2023, 17:00:22 UTC
Previous filing
03 Mar 2023
Next filing
05 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Award $0 +139,067 $0.000000 139,067 07 Mar 2023 Common Stock 139,067 $23.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on April 7, 2023.